The only reported application of ImmunoPET was [89Zr]bevacizumab in diffuse intrinsic pontine glioma to study vascular endothelial growth factor (VEGF) excretion and the potential to treat these patients with bevacizumab (61). Here, VEGFA is linked to diffuse intrinsic pontine glioma.